At a glance
ClinicalIndex Comparison Record- ✓Aged 18 years or older
- ✓Pathologically confirmed esophagogastric adenocarcinoma
- ✓Metastatic or recurrent disease
- ✓ECOG performance status 0-1
- ✕Pregnant or lactating
- ✕Active HIV infection
- ✕Active hepatitis C or B virus infection requiring treatment
- ✕Receiving therapy for concurrent active malignancy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Trial of Intraperitoneal Mesothelin-Targeted CAR T-Cell Therapy in Patients With Mesothelin-Positive Esophagogastric Adenocarcinoma With Peritoneal Carcinomatosis
In Brief
A Phase 1 clinical trial evaluating M28z1XXPD1DNR CAR for Mesothelin Positive and 7 related conditions. Currently recruiting, targeting 18 participants across 7 sites.
Detailed Summary
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.
Study Details
Timeline
Interventions
Participants with esophagastric adenocarcinoma will be treated with an intraperitoneal infusion of different doses of autologous T cells that have been genetically modified ex vivo to express the M28z1XXPD1DNR CAR. The CAR T cells will be manufactured in MSK's Center for Cell Engineering.